Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Theravance Biopharma's Enterprise Value is €455.95 Mil.
Theravance Biopharma's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 was €233.06 Mil. Therefore, Theravance Biopharma's EV-to-FCF for today is 1.96.
The historical rank and industry rank for Theravance Biopharma's EV-to-FCF or its related term are showing as below:
FRA:0TB'
s EV-to-FCF Range Over the Past 10 Years
Min: -46.89 Med: -6.49 Max: 14.76
Current: 1.93
During the past 13 years, the highest EV-to-FCF of Theravance Biopharma was 14.76. The lowest was -46.89. And the median was -6.49.
FRA:0TB's EV-to-FCF is ranked better than 69.94% of 346
companies
in the Biotechnology industry
Industry Median: 14.31
vs FRA:0TB: 1.93
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Theravance Biopharma's PE Ratio (TTM) for today is calculated as:
Theravance Biopharma's share price for today is €14.60.
Theravance Biopharma's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €1.892.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Theravance Biopharma EV-to-FCF Related Terms
Theravance Biopharma EV-to-FCF Historical Data
* Premium members only.
The historical data trend for Theravance Biopharma's EV-to-FCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Theravance Biopharma's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Theravance Biopharma EV-to-FCF vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Theravance Biopharma's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where Theravance Biopharma's EV-to-FCF falls into.
Theravance Biopharma's current Enterprise Value is €455.95 Mil.
Theravance Biopharma's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €233.06 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Theravance Biopharma (FRA:0TB) has a EV-to-FCF of 1.96 as of Jul. 30, 2026. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Theravance Biopharma and its competitors. According to the industry distribution chart, Theravance Biopharma ranks #104 out of 346 companies in the Biotechnology industry, placing it in the top 30.1%.
Is Theravance Biopharma's EV-to-FCF too high?
Theravance Biopharma's current EV-to-FCF is 1.96. The Biotechnology industry median EV-to-FCF is 14.31. Theravance Biopharma's value of 1.96 is 86.3% below this industry median. Based on the distribution chart, Theravance Biopharma ranks #104 out of 346 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Theravance Biopharma has a GF Score™ of 72/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Theravance Biopharma's EV-to-FCF compare to ABUS and SANA?
According to the Biotechnology industry distribution chart, Theravance Biopharma ranks #104 out of 346 companies for EV-to-FCF. This puts Theravance Biopharma in the upper half of its industry. The industry median EV-to-FCF is 14.31. Theravance Biopharma's value of 1.96 is 86.3% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-FCF for a Biotechnology company?
The median EV-to-FCF among Biotechnology companies is 14.31, based on 346 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-FCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-FCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Theravance Biopharma's current EV-to-FCF of 1.96 is 86.3% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-FCF mean?
A high EV-to-FCF can signal that a stock is expensive relative to its fundamentals. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Theravance Biopharma and its competitors. For the Biotechnology industry, the median EV-to-FCF is 14.31 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Theravance Biopharma's current EV-to-FCF is 1.96. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Theravance Biopharma stock overvalued right now?
Based on GuruFocus' analysis, Theravance Biopharma (FRA:0TB) is currently considered Modestly Undervalued. The stock's GF Value™ is €16.18, compared to a current price of €14.60 — trading 9.8% below its estimated fair value. The current EV-to-FCF is 1.96 and 86.3% below the Biotechnology industry median of 14.31. Theravance Biopharma's overall GF Score™ is 72/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-FCF calculated?
EV-to-FCF is calculated from a company's financial statements. For Theravance Biopharma (FRA:0TB), the current EV-to-FCF is 1.96 as of Jul. 30, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Theravance Biopharma (FRA:0TB) Overvalued in 2026?
Based on GuruFocus' analysis, Theravance Biopharma stock appears to be undervalued.
The current stock price of €14.60 is trading 9.8% below its estimated GF Value™ of €16.18.
GuruFocus considers Theravance Biopharma to be Modestly Undervalued.
Key valuation signals for FRA:0TB:
EV-to-FCF: 1.96
GF Value™: €16.18 vs. price of €14.60 (9.8% below fair value)
Industry Position: 86.3% below the Biotechnology median (#104 of 346)
No single metric tells the full story. See the FRA:0TB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Theravance Biopharma Inc is a biopharmaceutical company focused on the development and commercialization of medicines to improve patients lives. The company leverages decades of expertise and has developed FDA-approved YUPELRI (revefenacin) inhalation solution for the maintenance treatment of patients with COPD. Its ampreloxetine Phase 3 clinical study (CYPRESS) for the treatment of symptomatic neurogenic orthostatic hypotension in patients with multiple system atrophy did not meet its primary endpoint. The company operates in a single segment, the development and commercialization of human therapeutics, and operates in the United States, which generates maximum revenue, and Europe.
72GF Score
Get the complete analysis for FRA:0TB
EV-to-FCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:0TB has been successfully added to your 
